Windsor, Alberta 11/24/2009 1:30:00 AM
News / Business

China Yongxin Pharmaceuticals Inc (OTC:CYXN) Announces Q2 2009 Earnings

China Yongxin Pharmaceuticals, Inc. (OTC:CYXN) has released the financial results for the second quarter ending June 30, 2009.  Revenues for the second quarter were reported at $14.6 million, a slight increase from the previous year’s second quarter.  Revenues from the company’s retail drug stores were at $6.0 million, up from the previous year’s second quarter revenues of $5.8 million.

 

Free Hot Penny Stocks, an online financial publication, provides investors timely stock market alerts. Free hot penny stocks profiles stock picks that could generate higher returns than average. These penny stocks include stocks with news, chart breakouts or increased volume.

Sign Up Today for our Penny Stock Newsletter

 

Founded in 1993, China Yongxin Pharmaceuticals was originally Changchun Yongxin Dirui Medical Co., Ltd.  A wholesale drug distributor, the company’s products include traditional Chinese medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment.  The company’s retail operations have been running since 2004 and gained franchise rights in 2005.

 

Sign Up for Free Hot Penny Stocks’ FREE Penny Stock Newsletter.

 

About Us

 

Free Hot Penny Stocks is a financial website and independent electronic publication that provides information and free penny stock alerts on selected publicly traded companies. We also track small cap companies and other stocks that may be positioned to break out. These penny stocks might have news, increased volume or chart breakouts. These penny stocks that are alerted could generate greater than average returns. Feel free to visit our penny stock forum to discuss other penny stock picks or penny stocks that you might own.

 

Free Hot Penny Stocks is not a registered investment advisor or broker-dealer. Please do your own Due Diligence before investing in any of the stocks mentioned above. To feature a company on our web site please contact us at the email listed below.

 

Please click here to read the full disclaimer